Free Trial

Avinger Q2 2023 Earnings Report

Avinger logo
$0.48 -0.23 (-32.61%)
(As of 12/20/2024 05:40 PM ET)

Avinger EPS Results

Actual EPS
-$8.85
Consensus EPS
-$7.35
Beat/Miss
Missed by -$1.50
One Year Ago EPS
N/A

Avinger Revenue Results

Actual Revenue
$2.04 million
Expected Revenue
$2.30 million
Beat/Miss
Missed by -$260.00 thousand
YoY Revenue Growth
N/A

Avinger Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Collect $7k per month from Tesla’s SECRET dividend (Ad)

Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69% dividend from Tesla… Which could put up to $7,013 in your pocket every month…

Click here to discover the new #1 way to invest in Tesla

Avinger Earnings Headlines

Financial Review: Surmodics (NASDAQ:SRDX) vs. Avinger (NASDAQ:AVGR)
Avinger’s 2024 Stockholder Meeting and Director Elections
Collect $7k per month from Tesla’s SECRET dividend
Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69% dividend from Tesla… Which could put up to $7,013 in your pocket every month…
Avinger (NASDAQ:AVGR) Now Covered by StockNews.com
Avinger, Inc. Reports Q3 2024 Results and Strategic Advances
See More Avinger Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Avinger? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avinger and other key companies, straight to your email.

About Avinger

Avinger (NASDAQ:AVGR), a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is based in Redwood City, California.

View Avinger Profile

More Earnings Resources from MarketBeat

Upcoming Earnings